drugset / Trial / NCT00648583

Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

NCT00648583

Phase 1 Completed 28 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelBasic science

Summary

The objective of this study was to investigate the bioequivalence of Mylan's ondansetron 24 mg tablets to GSK's Zofran® 24 mg tablets following a single, oral 24 mg (1 x 24 mg) dose administered under fed conditions.

Timeline

Start
2003-07
Primary completion
2003-07
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 24 mg Oral

Indications

No indication recorded.